02 Mar 2021
Hologic, Inc. (Marlborough, MA, USA) has acquired Diagenode (Liège, Belgium), a developer and manufacturer of molecular diagnostic assays and epigenetics products, which is expected to diversify its diagnostic business across test menu, customer segments and geography.
04 Feb 2021
Hologic, Inc. (Marlborough, MA, USA) and Google Cloud have entered into a new agreement to focus on enhancing artificial intelligence (AI) and machine learning (ML) to bring about breakthrough results in cervical cancer screening.
07 Jan 2021
Hologic, Inc. (Marlborough, MA, USA) has agreed to acquire Biotheranostics, Inc. (San Diego, CA, USA), a privately held, commercial-stage company that provides molecular diagnostic tests for breast and metastatic cancers, for approximately USD 230 million.
05 Jan 2021
Hologic, Inc. (Marlborough, MA, USA) has completed the acquisition of SOMATEX Medical Technologies GmbH (Berlin, Germany), a leader in biopsy site markers and localization technologies, for approximately USD 64 million.
02 Dec 2020
Hologic, Inc. (Marlborough, MA, USA) has received US Food and Drug Administration (FDA) clearance for its Genius AI Detection technology, a new deep learning-based software designed to help radiologists detect subtle potential cancers in breast tomosynthesis images.
20 Aug 2020
Hologic, Inc. (Marlborough, MA, USA) showcased its latest advances and shared its new innovations on its virtual booth at the online ECR 2020 event held on July 15-21.
15 Dec 2016
US medical device maker Hologic, Inc. has agreed to sell off its share of the Procleix blood-screening business to long-time partner, Grifols SA, for USD 1.85 billion in cash.